(Reuters) - Aveo Pharmaceuticals Inc said a combination of its experimental drug to treat a type of lung cancer and the standard of care did not significantly improve the response and survival rate in a mid-stage study. A combination of Aveo's ficlatuzumab and AstraZeneca's anti-cancer drug gefitinib, which is marketed as Iressa, was tested against gefitinib on Asian patients with non-small cell lung cancer. ... Get the complete story
No comments:
Post a Comment